Capricor的Deramiocel BLA因重大修订将PDUFA目标日延后三个月

----- 0001104659-26-100071-index-headers.html -----
<SEC-DOCUMENT>0001104659-26-100071-index.html : 20260824
<SEC-HEADER>0001104659-26-100071.hdr.sgml : 20260824
<ACCEPTANCE-DATETIME>20260824092530
ACCESSION NUMBER: 0001104659-26-100071
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 13
CONFORMED PERIOD OF REPORT: 20260824
ITEM INFORMATION: Other Events
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260824
DATE AS OF CHANGE: 20260824
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CAPRICOR THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001133869
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
EIN: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34058
FILM NUMBER: 261306665
BUSINESS ADDRESS:
STREET 1: 10865 ROAD TO THE CURE
STREET 2: SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (310) 358-3200
MAIL ADDRESS:
STREET 1: 10865 ROAD TO THE CURE
STREET 2: SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Nile Therapeutics, Inc.
DATE OF NAME CHANGE: 20070920
FORMER COMPANY:
FORMER CONFORMED NAME: SMI PRODUCTS INC
DATE OF NAME CHANGE: 20010206
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>capr-20260824x8k.htm
<DESCRIPTION>8-K
<TEXT>
Document 1 - file: capr-20260824x8k.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>capr-20260824xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
Document 2 - file: capr-20260824xex99d1.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>capr-20260824xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
Document 3 - file: capr-20260824xex99d1001.jpg
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>capr-20260824.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
Document 4 - file: capr-20260824.xsd
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>capr-20260824_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
Document 5 - file: capr-20260824_lab.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>capr-20260824_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
Document 6 - file: capr-20260824_pre.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 8 - file: R1.htm
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 9 - file: report.css
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 10 - file: Show.js
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 12 - file: FilingSummary.html
Document 12 - RAW XML: FilingSummary.xml
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 14 - file: MetaLinks.json
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-26-100071-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 15 - file: 0001104659-26-100071-xbrl.zip
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>capr-20260824x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
Document 16 - file: capr-20260824x8k_htm.html
Document 16 - RAW XML: capr-20260824x8k_htm.xml
</DOCUMENT>
</SEC-DOCUMENT>

----- 0001104659-26-100071.txt -----
0001104659-26-100071.txt : 20260824
0001104659-26-100071.hdr.sgml : 20260824
20260824092530
ACCESSION NUMBER: 0001104659-26-100071
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 13
CONFORMED PERIOD OF REPORT: 20260824
ITEM INFORMATION: Other Events
ITEM INFORMATION: Financial Statements and Exhibits
FILED AS OF DATE: 20260824
DATE AS OF CHANGE: 20260824
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CAPRICOR THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001133869
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
EIN: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34058
FILM NUMBER: 261306665
BUSINESS ADDRESS:
STREET 1: 10865 ROAD TO THE CURE
STREET 2: SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (310) 358-3200
MAIL ADDRESS:
STREET 1: 10865 ROAD TO THE CURE
STREET 2: SUITE 150
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Nile Therapeutics, Inc.
DATE OF NAME CHANGE: 20070920
FORMER COMPANY:
FORMER CONFORMED NAME: SMI PRODUCTS INC
DATE OF NAME CHANGE: 20010206
8-K
1
capr-20260824x8k.htm
8-K
CAPRICOR THERAPEUTICS, INC._August 24, 2026
​
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
​
FORM
8-K
​
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
​
Date of Report (Date of earliest event reported)
​
August 24, 2026
​
CAPRICOR THERAPEUTICS, INC.
(Exact name of Registrant as Specified in its Charter)
​
​ ​ ​
​
​
Delaware
​ ​ ​
001-34058
​ ​ ​
88-0363465
(State or other jurisdiction
of incorporation)
​
(Commission
File Number)
​
(I.R.S. Employer
Identification No.)
​
​
​ ​ ​
10865 Road to the Cure, Suite 150
,
San Diego
,
California
(Address of principal executive offices)
​ ​ ​
92121
(Zip Code)
​
(
858
)
727-1755
(Registrant’s telephone number, including area code)
​
Not Applicable
(Former name or former address, if changed since last report)
​
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
​
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
​
Emerging growth company
☐
​
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
◻
​
Securities registered pursuant to Section 12(b) of the Act:
​
​ ​
Title of Each Class
​ ​ ​
Trading Symbol(s)
​ ​ ​
Name of Each Exchange on Which
Registered
Common Stock, par value $0.001 per share
CAPR
The
Nasdaq
Global Select Market
​
​
​
​
Item 8.01
Other Events.
​
On August 24, 2026, Capricor Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has extended the Prescription Drug User Fee Act (“PDUFA”) target action date for its Biologics License Application (“BLA”) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy ("DMD"), from August 22, 2026 to November 22, 2026. The FDA has classified the submission as a major amendment, which extends the review period by three months. The amendment includes 24-month open-label extension data from Capricor’s pivotal Phase 3 HOPE-3 study, and additional analyses with a request for FDA’s review of the existing and new data in support of a refined proposed indication focused on upper limb function, the primary endpoint of HOPE-3.
​
A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
​
Item 9.01
Financial Statements and Exhibits.
​
(d) Exhibits
​
99.1
​
Press Release, titled “Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA”, dated August 24, 2026.
​
​
​
104
​
Cover Page Interactive Data File (formatted as inline XBRL).
​
​
2
​
SIGNATURES
​
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
​
CAPRICOR THERAPEUTICS, INC.
Date: August 24, 2026
By:
/s/ Linda Marbán, Ph.D.
Linda Marbán, Ph.D.
Chief Executive Officer
​
​
3
EX-99.1
2
capr-20260824xex99d1.htm
EX-99.1
Exhibit 99.1
Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication –
SAN DIEGO
, Aug. 24, 2026 (GLOBE NEWSWIRE) —
Capricor Therapeutics
(NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD), from August 22, 2026 to November 22, 2026.
As part of its ongoing discussions with the FDA following the July 2026 Advisory Committee meeting, Capricor submitted an amendment to the BLA that includes 24-month open-label extension data from its pivotal Phase 3 HOPE-3 study and additional robustness analyses, with a request that the FDA review the existing and new data in support of a refined proposed indication focused on upper limb function, the primary endpoint of HOPE-3. The FDA's Center for Biologics Evaluation and Research (CBER) accepted the amendment for review, citing the significant unmet medical need in DMD. The FDA has classified the submission as a major amendment and extended the PDUFA target action date by three months to allow additional time to review the information.
“With an additional year of follow-up from HOPE-3, we now have one of the most extensive clinical datasets evaluating upper limb function in Duchenne,” said Linda Marbán, Ph.D., Chief Executive Officer of Capricor. “HOPE-3 met its primary endpoint, demonstrating a statistically significant benefit in upper limb function, and we believe the additional open-label data and further analyses included in the amendment strengthen the evidence supporting a refined proposed indication. We appreciate the FDA’s continued engagement and look forward to working constructively with the agency as it completes its review.”
Marbán continued, “The powerful testimony shared by patients, families and clinicians at the July Advisory Committee meeting underscored the importance of preserving upper limb function and the independence it provides for people living with Duchenne. In a progressive disease where function, once lost, cannot be recovered, we believe preservation of upper limb function has the potential to translate into meaningful differences in patients' independence and daily lives. That impact reinforces the urgency of our work and our commitment to bringing Deramiocel to the Duchenne community as soon as possible.”
About Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration affecting the skeletal, respiratory, and cardiac muscles. It is caused by the absence of functional dystrophin, a key structural protein in muscle cells. DMD affects approximately 15,000 individuals in the United States and primarily impacts boys. Over time, deterioration of the heart muscle leads to cardiomyopathy and heart failure, which is the leading cause of death in DMD. There is no cure, and treatment options remain limited.
About Deramiocel
Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs), a rare population of cardiac cells that have been shown in preclinical and clinical studies to exert immunomodulatory and anti-fibrotic actions in the preservation of skeletal and cardiac muscle function in muscular dystrophies such as DMD. CDCs act by secreting extracellular vesicles known as exosomes, which target macrophages and alter their expression profile to adopt a healing rather than pro-inflammatory phenotype. For the treatment of DMD, Deramiocel holds Orphan Drug, RMAT and Rare Pediatric Disease designations in the
U.S., and Orphan Drug and ATMP designations in Europe. The Rare Pediatric Disease Designation may qualify Capricor for a Priority Review Voucher upon approval.
About Capricor Therapeutics
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing cell and exosome-based therapeutics for the treatment of rare diseases. Our lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage development for Duchenne muscular dystrophy (DMD), evaluated in clinical studies for its potential to preserve skeletal and cardiac muscle function. Capricor is also advancing its proprietary StealthX™ exosome platform for the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics across a range of diseases. At Capricor, we are committed to delivering new therapies for patients with rare diseases. For more information, visit
capricor.com
, and follow Capricor on
Facebook
,
Instagram
and
X
.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor’s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval, revenue and reimbursement estimates, projected terms of definitive agreements, our financial position, our possible uses of existing cash and investment resources; results of securities litigation; and statements regarding our litigation with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc., including the nature of the dispute, our expectations regarding any legal proceedings, and our ability to commercialize Deramiocel independent of our existing distribution agreement and any other statements about Capricor’s management team’s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “believes,” “plans,” “could,” “anticipates,” “expects,” “estimates,” “should,” “target,” “will,” “would” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor’s business is set forth in Capricor’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026 and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, as filed with the Securities and Exchange Commission on August 14, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
Deramiocel and the StealthX™ vaccine are investigational candidates and have not been approved for commercial use in any indication.
For more information, please contact:
Capricor Media Contact:
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
ckasunich@kcsa.com
/
rcona@kcsa.com
212.896.1241 / 516.779.2630
​
Capricor Company Contact:
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com
858.727.1755
GRAPHIC
3
capr-20260824xex99d1001.jpg
GRAPHIC
begin 644 capr-20260824xex99d1001.jpg
M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" !< /,# 2( A$! Q$!_\0
M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4%
M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B
7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$!
M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** &2
MRI!&TDCK'&HRS,< #U)KC!\:?!#7@MO^$CM-Y?RPYW",MZ>9C;^M0_%2W.KG
MP]H
YK2G[2"D%%%%9&H4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!RVM
MSWVM:^-%LKM]/@BA$]U
803A44G@9P236)XITG5/ VF2ZYI&K7MZMF/-N
M+"_E\U)HQ][:2,JV.F*W[!MOCG6B>@M(#^K5XK=Z'??&'2?%?B;6=4O(=(LW
MGM].TVUF,
_3^MCR<1.R?*FY.]M;6M_7S/0
M/B/XLT^P/@?7+B1UL7O!*#'&TCD-$2 %4$D\] *[+PWXVT?Q7:SS6%RW^CG$
M\5Q$T,D7?YD< BOFVYM'^"^N^!]7M9[[Q#97D 8:*\IEEC=D&6B7GUKT#P3X
MWLO'OQ&UVUOK&\\.WEU8BWBL+Z$Q33)@Y?GC(S757P,?8J4+N*3=_P#M[:V_
MSO8YZ.,E[5QE9-M:?+>^WR+FF^*9['1_&,VCAY-0:[-Q &MW):$L 944@>8
M,GY<]*ZOX6:]J>O:??O>W#W]M%/LM;^2V:W:=-H).P@=#D9QVJE\/K6\U#6K
MJ>_NDF&C%].MECCV97C+-ZG@5Z+7!BJD%S4U'5VU^[R_J[.S#TYNTW+1=/Z?
M]6"BBBO+/2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** .8M/\ D==<_P"O.'_V>O./AK_R0WQ)_P!?%_\ ^A&N^\2Q
MZAH&M'7+*QEU2UEM_L]Y:VV#,H!)61 2-V,D$=?3->/_ SU/5O$OP^O?"^C
M:5>QR7E_
EX7\K7O<\6M/EJJ+6
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M9K[3;\^%O#.\A)1*T$6/12H+R'WZ>]>7.C[:
E"I[*"@U>78^Z0RM
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M+13$FCD.%=6/L
@)ZT .HHHH ;)_JV^AKS?X!?\B7>_P#86N__ $97I+#
7 *PW$4C;N&Z CT->C0A*K0J0@KO1V\E?_ #.&
MM.-.M3G-V6JO]W^1/^T'90/?^#9#& \^J);RLI(,D9&2C8ZCV->QPPI;Q)%$
MBQQH JHHP !V%>$^+/$]M\8_B#X8T?PTQU#3]*NQ?7NHQJ?)3 X4-W->\U>+
M4J=&C3GHTF[=KO0C#.,ZM6I#5-K7T6I\-?M/2S_%']I7PUX):1A81R11% ?[
MWS.?K@&OM?1-&M/#VDVFFV$*6]I;1K%'&@P ,5\2_M%M)\,?VJ_#GBVX0C3
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M$E&'7@U]VZ?>QZC8V]U$
!=X^RF%1-NZ;//\ F_3-?:FG
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MS1X9D#QF6 E2/05]R 8%;UJKI4X**U:W,J5-5)R
:_';X)Z9\;?"+:;=.+748,R65Z!DQ/Z'U4]Q7ROX<^)7Q>_97
^#G%>
$[/0O$O@W6TU?3XA;C[)$I23;P,ABI4_@
M:^PJJRZ99SR^;+:022?WWC4G\\5,*\>3V=2-TMNA4J4N?G@[,_/#]HSQEX[^
M,5II7B/4/#EQH?AB.
M"+&-@DES:^2K-T!:; )_.M'P]^T=\1/V?[2/PKXZ\&W&MQV2B*UOXI#&9(QP
MN'VLKC'0\'UIG[;O_)9_AO\ [L?_ *4BOKGQ!JD>EZ:LLVD7&J6ZQEW\A8F"
M #J0[K^F:[N9>RIPE'FO?R_$Y.5^TG)2M8^*?&_Q5^(_[5\T/A?P[X8FT30Y
M'!N&9F8$9ZR2%5 ] /SKZ]^#_PRLOA)X#T_P]9MYK0KOGGQCS93]YO\^E;6
MDZPLFF2W(TBYTR"-/,5)A$-XQG@([?KBKVG:M;:G;P21R('EC63RBX+*",\C
M\:Y*U24H\D8VBOF=%*"4N:3NV?)W[?UE<7=OX2\B"2;;,^?+0MCIZ5]5^&05
M\.:4",$6L0(/^X*LWTEG&JF\:!5SA3.5 S[9J
4.
MLFX;1^-1VGV28&>V\EPW62+!S^(HIU'3C*-M] G!3E%WV*OB7P]9^+- U#1]
M0C$UE>PM!*A[JPQ7Q-IDGQ'_ &,_$M_;1:/)XE\&W4N^-T#;&'8[@#L?'!R,
M&ON;[;;^:L?GQ>8W1-XR?PHNI8(H&-R\:0]"92 OZU5*JZ:<6KI]":E-3]Y.
MS74^-_$/[<'B3Q;8-I7@[P+>6NKW(\M9Y9#.R$_W55!S[D_A7T+\ [+QQ9^
M;8^/;L7&L2'>J%1YD2'HKD=37>VEI80+Y]K#;1J1GS(44 CZBK)E0!277YCA
M>>OTHJ582CR0A;\6$(23YIRN?+_[4WP!U[6=?LOB%X%5G\0V!5Y[6(XDDV_=
M=/4CH5[^]
+F;6(1L>2&9H [#U1HR0?H:^OVUBR34?L#
M7,:WFP2>46P<$X'\JCFM;6[U)HYM/BE*QAQ<2*C
-8HT'90,"G"YMXI5MQ+$DF.(MP!Q["EFO+>
MV95FGCB9ONAW )^F:RK595;)*R6R-*=-4[MN[>[/B[XA6-R_[;NC3+;RM")(
M
]?:]
)B\2,PVL5!(]
M#55Y.48-K96)HI*4DNX^BBBN,Z0HHHH **** "BBB@ HHHH **** "BBB@#Y
M _;&\):UK_Q<^']SINE7=];VZQ^;+;PLZQ_Z0#R1TXYKZJU^)Y/#-_&BEG:U
M
OYUW%%3&JXZ(
W^Q- $3[3
M8M
IZ5VU%6L1)**[6
M_ AT(WD^_P"IS_B2)-/T&.&WLH6M_,175H2\<2YY
6Z:VG2>']2MVTZ>75
M9+RZ$)6(F1V\Y]K(_8#ZC&*Z#Q/IMW+-I4MQ)"UO#$5F,UJ;A/,P/F*AA[\\
M]:ZJRL8=/@\F!-D>]GQGNS%B?S)JQ6LL1[_-%=_Q,XT/=Y6^WX'):+H[0^&M
M3B@F\X7(D,:+;&!%)7&%4D\&J*:LM^_AFSAM[DS6]POVC="RB+$;#YB?>N[H
MJ/;ZMM7_ .&L7['1)/\ K
BK]O[W-;\?^ 9^Q]WE_0ALY#+:0NT9A9D!,9_AXZ5-117,SH04444AG__
!V0$!
end
EX-101.SCH
4
capr-20260824.xsd
EX-101.SCH
00090 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
EX-101.LAB
5
capr-20260824_lab.xml
EX-101.LAB
Document and Entity Information [Abstract]
Document Type
Document Period End Date
Entity File Number
Entity Registrant Name
Entity Incorporation, State or Country Code
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Postal Zip Code
City Area Code
Local Phone Number
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
Trading Symbol
Security Exchange Name
Entity Emerging Growth Company
Entity Central Index Key
Amendment Flag
EX-101.PRE
6
capr-20260824_pre.xml
EX-101.PRE
XML
8
R1.htm
IDEA: XBRL DOCUMENT
Document and Entity Information
Aug. 24, 2026
Document and Entity Information [Abstract]
Document Type
8-K
Document Period End Date
Aug. 24, 2026
Entity File Number
001-34058
Entity Registrant Name
CAPRICOR THERAPEUTICS, INC.
Entity Incorporation, State or Country Code
DE
Entity Tax Identification Number
88-0363465
Entity Address, Address Line One
10865 Road to the Cure, Suite 150
Entity Address, City or Town
San Diego
Entity Address, State or Province
CA
Entity Address, Postal Zip Code
92121
City Area Code
858
Local Phone Number
727-1755
Written Communications
false
Soliciting Material
false
Pre-commencement Tender Offer
false
Pre-commencement Issuer Tender Offer
false
Title of 12(b) Security
Common Stock, par value $0.001 per share
Trading Symbol
CAPR
Security Exchange Name
NASDAQ
Entity Emerging Growth Company
false
Entity Central Index Key
0001133869
Amendment Flag
false
XML
9
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
.report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
.report table.authRefData a {
display: block;
font-weight: bold;
}
.report table.authRefData p {
margin-top: 0px;
}
.report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
.report table.authRefData .hide a:hover {
background-color: #2F4497;
}
.report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
.report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
.pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
.report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
.report hr {
border: 1px solid #acf;
}
/* Top labels */
.report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
.report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
.report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
.report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
.report td.pl div.a {
width: 200px;
}
.report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
.report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
.report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
.report .re, .report .reu {
background-color: #def;
}
.report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
.report .ro, .report .rou {
background-color: white;
}
.report .rou td {
border-bottom: 1px solid black;
}
.report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
.report .fn {
white-space: nowrap;
}
/* styles for numeric types */
.report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
.report .nump {
padding-left: 2em;
}
.report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
.report .text {
text-align: left;
white-space: normal;
}
.report .text .big {
margin-bottom: 1em;
width: 17em;
}
.report .text .more {
display: none;
}
.report .text .note {
font-style: italic;
font-weight: bold;
}
.report .text .small {
width: 10em;
}
.report sup {
font-style: italic;
}
.report .outerFootnotes {
font-size: 1em;
}
XML
10
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
12
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.26.1
html
1
22
1
false
0
0
false
0
false
false
R1.htm
00090 - Document - Document and Entity Information
Sheet
http://capricor.com/role/DocumentDocumentAndEntityInformation
Document and Entity Information
Cover
1
false
false
All Reports
Book
All Reports
capr-20260824.xsd
capr-20260824_lab.xml
capr-20260824_pre.xml
capr-20260824x8k.htm
http://xbrl.sec.gov/dei/2025
true
false
JSON
14
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"version": "2.2",
"instance": {
"capr-20260824x8k.htm": {
"nsprefix": "capr",
"nsuri": "http://capricor.com/20260824",
"dts": {
"schema": {
"local": [
"capr-20260824.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
"https://xbrl.sec.gov/dei/2025/dei-2025.xsd"
]
},
"labelLink": {
"local": [
"capr-20260824_lab.xml"
]
},
"presentationLink": {
"local": [
"capr-20260824_pre.xml"
]
},
"inline": {
"local": [
"capr-20260824x8k.htm"
]
}
},
"keyStandard": 22,
"keyCustom": 0,
"axisStandard": 0,
"axisCustom": 0,
"memberStandard": 0,
"memberCustom": 0,
"hidden": {
"total": 2,
"http://xbrl.sec.gov/dei/2025": 2
},
"contextCount": 1,
"entityCount": 1,
"segmentCount": 0,
"elementCount": 23,
"unitCount": 0,
"baseTaxonomies": {
"http://xbrl.sec.gov/dei/2025": 22
},
"report": {
"R1": {
"role": "http://capricor.com/role/DocumentDocumentAndEntityInformation",
"longName": "00090 - Document - Document and Entity Information",
"shortName": "Document and Entity Information",
"isDefault": "true",
"groupType": "document",
"subGroupType": "",
"menuCat": "Cover",
"order": "1",
"firstAnchor": {
"contextRef": "Duration_8_24_2026_To_8_24_2026_PFRDhXLmvEGk3Oggf1lnIQ",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "capr-20260824x8k.htm",
"first": true,
"unique": true
},
"uniqueAnchor": {
"contextRef": "Duration_8_24_2026_To_8_24_2026_PFRDhXLmvEGk3Oggf1lnIQ",
"name": "dei:DocumentType",
"unitRef": null,
"xsiNil": "false",
"lang": "en-US",
"decimals": null,
"ancestors": [
"p",
"div",
"div",
"body",
"html"
],
"reportCount": 1,
"baseRef": "capr-20260824x8k.htm",
"first": true,
"unique": true
}
}
},
"tag": {
"dei_AmendmentFlag": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "AmendmentFlag",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
}
}
},
"auth_ref": []
},
"dei_CityAreaCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "CityAreaCode",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "City Area Code",
"documentation": "Area code of city"
}
}
},
"auth_ref": []
},
"dei_CoverAbstract": {
"xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "CoverAbstract",
"lang": {
"en-us": {
"role": {
"label": "Document and Entity Information [Abstract]",
"documentation": "Cover page."
}
}
},
"auth_ref": []
},
"dei_DocumentPeriodEndDate": {
"xbrltype": "dateItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentPeriodEndDate",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Document Period End Date",
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
}
}
},
"auth_ref": []
},
"dei_DocumentType": {
"xbrltype": "submissionTypeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "DocumentType",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Document Type",
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
}
}
},
"auth_ref": []
},
"dei_EntityAddressAddressLine1": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressAddressLine1",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Address Line One",
"documentation": "Address Line 1 such as Attn, Building Name, Street Name"
}
}
},
"auth_ref": []
},
"dei_EntityAddressCityOrTown": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressCityOrTown",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, City or Town",
"documentation": "Name of the City or Town"
}
}
},
"auth_ref": []
},
"dei_EntityAddressPostalZipCode": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressPostalZipCode",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, Postal Zip Code",
"documentation": "Code for the postal or zip code"
}
}
},
"auth_ref": []
},
"dei_EntityAddressStateOrProvince": {
"xbrltype": "stateOrProvinceItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityAddressStateOrProvince",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Address, State or Province",
"documentation": "Name of the state or province."
}
}
},
"auth_ref": []
},
"dei_EntityCentralIndexKey": {
"xbrltype": "centralIndexKeyItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityCentralIndexKey",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Central Index Key",
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityEmergingGrowthCompany": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityEmergingGrowthCompany",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Emerging Growth Company",
"documentation": "Indicate if registrant meets the emerging growth company criteria."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityFileNumber": {
"xbrltype": "fileNumberItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityFileNumber",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
}
}
},
"auth_ref": []
},
"dei_EntityIncorporationStateCountryCode": {
"xbrltype": "edgarStateCountryItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityIncorporationStateCountryCode",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Incorporation, State or Country Code",
"documentation": "Two-character EDGAR code representing the state or country of incorporation."
}
}
},
"auth_ref": []
},
"dei_EntityRegistrantName": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityRegistrantName",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Registrant Name",
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_EntityTaxIdentificationNumber": {
"xbrltype": "employerIdItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "EntityTaxIdentificationNumber",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Entity Tax Identification Number",
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
}
}
},
"auth_ref": [
"r1"
]
},
"dei_LocalPhoneNumber": {
"xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "LocalPhoneNumber",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Local Phone Number",
"documentation": "Local phone number for entity."
}
}
},
"auth_ref": []
},
"dei_PreCommencementIssuerTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "PreCommencementIssuerTenderOffer",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Issuer Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
}
}
},
"auth_ref": [
"r3"
]
},
"dei_PreCommencementTenderOffer": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "PreCommencementTenderOffer",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Pre-commencement Tender Offer",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
}
}
},
"auth_ref": [
"r5"
]
},
"dei_Security12bTitle": {
"xbrltype": "securityTitleItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "Security12bTitle",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Title of 12(b) Security",
"documentation": "Title of a 12(b) registered security."
}
}
},
"auth_ref": [
"r0"
]
},
"dei_SecurityExchangeName": {
"xbrltype": "edgarExchangeCodeItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "SecurityExchangeName",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Security Exchange Name",
"documentation": "Name of the Exchange on which a security is registered."
}
}
},
"auth_ref": [
"r2"
]
},
"dei_SolicitingMaterial": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "SolicitingMaterial",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Soliciting Material",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
}
}
},
"auth_ref": [
"r4"
]
},
"dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "TradingSymbol",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Trading Symbol",
"documentation": "Trading symbol of an instrument as listed on an exchange."
}
}
},
"auth_ref": []
},
"dei_WrittenCommunications": {
"xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/dei/2025",
"localname": "WrittenCommunications",
"presentation": [
"http://capricor.com/role/DocumentDocumentAndEntityInformation"
],
"lang": {
"en-us": {
"role": {
"label": "Written Communications",
"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
}
}
},
"auth_ref": [
"r6"
]
}
}
}
},
"std_ref": {
"r0": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b"
},
"r1": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "b-2"
},
"r2": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "12",
"Subsection": "d1-1"
},
"r3": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "13e",
"Subsection": "4c"
},
"r4": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14a",
"Subsection": "12"
},
"r5": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Exchange Act",
"Number": "240",
"Section": "14d",
"Subsection": "2b"
},
"r6": {
"role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC",
"Name": "Securities Act",
"Number": "230",
"Section": "425"
}
}
}
ZIP
15
0001104659-26-100071-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001104659-26-100071-xbrl.zip
M4$L#!!0 ( "YK&%WK8^*5 P, &L* 1 8V%P
"+[GGGM\OSRX798,O8%45/!AD$1Q@(#GHJ!\-@QJ/0U[P>WHP]7@
M8QB^WC^/42'RN@2N42Z!:"C0@NHY>A%513AZ BDI8^A>TF(&""5)U(GB*$%A
M.'(4]T09%\&1XTJCQ!L^-6R"9ZB'TPY.X_0&=;*DEW7[Z.[)XYZ,LBD]!URJ
M(E/Y'$J"-)$ST%])":HB.0R#N=95AG%.*DES(:-
(Z$G)F L4)?GT:
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M4L"4
STP3V%$3F!RP'^\J0B JDIJ"VUAW^5[=B9/+>
M6QD78/_E.@.\-US-P
[K]:
M"UEUPHIL]!=02P,$% @ +FL871;R>9-H!0 GSL !4 !C87!R+3(P
M,C8P.#(T7VQA8BYX;6S5FE%OXC@4A=\K[7^XR[[L2A/2T';4HI8193JC:NFT
M&ECM:%>K44@,6!MLY)@"_W[L)*8DM0,#)3(O;
?1&'M2RB+&\QB)++:LA7)ZR++]RT
MN)*^LL[:]ZZNKMRD6FN= &0SYP]0U!5'D%2:?#E%-S6TX(B$2*9-7F4T0B5I
M9=E=&4MK&N3\(CFME"F[,4/#U"Y6S<0HJ(_HLQLB+-_F"WG@R ,Y:;^)/[YW
MJ$"W/8@Y\P.NG)+X-S5=74[&5C/LJM#2J\WRR7T6J+'$X89YR!1N0 564^XD
MCNKT(:,3?=)T.*HI?H\&T
-]-]UFNB C*DL?>&H:;Q0MI
0# .40384
MR+&J0KKO+^Y#L4' 0YQ^U+#A:FW6VX[QAD[S !O$-J.[*?*>T I[R/M7?+UO
MAZ&8M#C[U<4$><:YT&MM)[2DPSR=&J'-9);%W9/*S/.=.@#I#H^DLO4S&[
,8?)7N*1/3'ZC$E@
MWI,:Y4="I*%/+98%[1&P:4K\5H"N=IQJA(HI?:(Q]Z-_\+3TOLD@/A)"M3UJ
M^
^G3];'Z%F^M9B=AVH2[,I5<
M@*5;10C)K^FCIS$EYL^Z-1)[43+UHW JUNU$RIAR5ZP20T@<*[OW_9MASA'I
MT,ED1K(;[UC3K$EG+V2EG2G2M"([<2N/NBMSF2OD;0_/78]&.,
AT/M
M);14;"]UFWM4])F5=E*X1=Y=:1363K#F#:DY).Z5
;C
Q8+(9@I-4??D+[.%Q!>$\>'):XN[
ME5#>L7R*_)&FWV+=7M*TG2C"
&ULU5I=C]HX%'T?:?^#-_N<3V *"*@8.EVA#ATT4+7:E\HD!JQ-
M[,@Q _S[M4,\A9! 9E<;Y!<(\?'UN>
9K,*=Q# F8(,9P
M&(('AH,5 L!UK:;E6"XPS4$:X@$FH@LE((WE6:YJ&&71*.F"MNTU;<_Q[D&S
MZ[:[K0X83A1N(I@M\35@B,G?7?FQ$.,!D2%)NKL$]XTUYW'7MK?;K;5M6)2M
M1'?'M7],GF;^&D70Q"3AD/C( +?3=*33]2'/)7GJ/MNP4(5H&&_C56*D+],
M!3/E*=/US(9K[9+ R"C*Y@J#*+ALQ1?P1[D<\&?Q,PW<3J=CIZW&X Z 'J,A
M>D%+D)[J\GV,^D:"HSB4H=)S:X:6?<.',3.E_D[;:\I$_OB4S0[U/23!(^&8
M[\=D25F4RF@ &?_;R_B-BHR#?
85,Y2(8&GO)]&6
M)2-'_.]
2!-;:6&BA\_1U2L#\-%PAGTN8H4
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M[=O9D*ZISVS*Z"L^5,07O
),O NOGR'7Z
MJMQS:C5$7KI#AF")!
8
]Q5R^KRE:JG(0+2RH1%I)7F^E/&=0
MOF>>[:,%+;HUG+1K(?9UQDKI>HMA-0D>=_X:DA4J><1=!--"]\K$E?RWJ'H?
M(\168G;\R>B6K\6Z&$.R+RU["]%:F/%>_NHU6[V%[X'E2"3(8#@6=Z3=%U3N
M1@ZGD0]5F"L'ZJV)AV)+$,AMP><0K@J4/VG70O'KC)72):5PS\[_1V5PU[,/
MPN##/ST&_P!02P,$% @ +FL87:$9\^-.%0 [I< !0 !C87!R+3(P
M,C8P.#(T>#AK+FAT;>T]^5/;.K>_?W^%'O?=6YC!B>TL)('VFY %4I:D64IO
MY\UD9%N)51S;>,G"7_^.9#LX"PD% H'2F0*VY:.CL^DLDGSTW_' 0$/BN-0R
M/W^2$N(G1$S5TJC9__RIV"K5:I_^^^4_1_\C"(C^.&Z>(\U2_0$Q/:0Z!'M$
M0R/JZ074MFP;F^B". XU#'3L4*U/PE
E
M$#![G$O*Z:0LREF4+DBY0B:+BA=W+8.7SZGB8&<2C:( T,1$/IO)).2L+,VW
M;A%G2%6"OEH*JI4+2 S_"4M^1/\"&+H'I )RF6Y!(_3SCNYY=B&9'"N.D7")
MFNA;PR0\8.AF=H*&TT:CT2@Q2B4LIY^4\OE\
'R# [LZ;0I=*EYLX,*,<@D
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MR5-R#B:_="W?X5=
Y0XB ^#++40I=K9+!?G
M7_X2W9J%;@,!+2VZ N5SO#+,+5\8GLRNR.GHO;MG4S2U>YI&3Z+KJ)/D#*DB
MNDX)F8QIS()V#?!8&%$-9E))%/\^M+'&9F#!(#VOD$ODY+M;#NWKTWN62QDG
MH!L#6#+DBAF#JAH$.P7%\O3#^0X6WAR = )!P[S=2:P G8$J0>#$GIX0(U)
MX5.;#HB++LD(-:T!-C_M!W?@MPNDZ'TZY*U=>DN@,P 4H0Z(>-:@(,5N,9/#
MKAG%!&S0OEE0@87$.50L!T@U?2
*B@]R!WE-8E8>O]3 E"7$S\$C?CD*
MY$ZQ# W:=BYK[4H9M=K%=J5UE%1>DOZ_@6:K4NHT:^U:I86*EV54^5$Z+5Z>
M5%"I?G%1:[5J]
8E+5CNB5)8K3
Z3;I=Y3!";7,?FIG#2^PXW<%7?7!N_Y ]\6;-)?@W%.. N4
M9-XEVX(987ODXJG6"0QILW+91LU*H]YL;Y'9;/B.ZV/30YZ%6D1E
((BF?2K\PMN]$=IFWSRC8
M)+;E>&@WN@;GV@!*>X@,64+,X8^)MO=!X=\>Q_//!T'^Y_,.'7L%#1@F# "H
MSF8)0<,380+,$XBY;-YH\'BN$D1YL0GDH)@>%MLN&5X+Y]K5U;>37W;_5W&-
M4BZD8NZ93)[! \M^.&#O7)7D]*NHTGP*KDGZU&5)5N\2GL0TQ&^
]6QAAF7D:\8/*(B(:PBUHV45GB
M2D/41-1S44G','
YL? ;]#398ZBYF'YTY 2#U9PR0K==-B/MM-R[U<5\FF
M>MV,>)"75%65\KF#, &!H\SH37'<\XR&_U,\*_[[P[.DWNGH:[$K=\7YEOF\
M:+1K0Z75(4._DOIY5LYG>$MYOF56;_YJC;[2DHBO6X.O_=M3JWO^#5JFPY8>
M5@PR-6]!2@E,FX%MEQ2B/^)4S0(M0FO'DFIACGXV91?/>@4).W9GUJIZ3M1K
MS':R^UIT?T@
12
)JO4( !?(
5SFW=\(L#D55ZY34L$45)
M2*7%3.XY)'"SU']JIO5#^IY%^MIX7 MKS"H'.">*^5RJ,JZ=]MS.B?PM-S&M
M2^G?S#<0Q?2ZO').$%/95#J;62V+;WQ26QD?\1F&Y5(M3R<.^N4[U-4H3[)R
MHJQZ^4AQV)2_IA6$730^I^UMK^.Y=JY9\+3B0WU99VLKI*=D#0;4=9]/6-A,
M@P+]?I2<; '!/F1D5D9JB6:BE4"5@6U8$^(\DZ#,S@CHTDK,R0LWVDF>6-C2
MJ.OED/J-].@;S<2D
JY.0FUWKI[$9:5U21Q%PV P3 &ENZ
M /XU*OD.V4
N=KV3/)>04K
MM/5S8EY7_-MUM&C!O%2FI&]MSYA_.S47$H6'3'6G 2TIWUPQI
V[;#27_+%;%2NX:P\J9XI>/6O5SKJ=
MLW4V(2]+LK0IH0<<$4-R.\*"W+:M]5E)NXU/,FQ>*8+C,R=%_4&F))]V?V8J
M]9OC2;W2:&0.UB[NR=V32E[USM[FY]%S"TQ&0[?,F
I8!G;/WF$-,68;7+;P"7YYK
MU=_#TEKA8D@QR$>M\ &Y?@ *AR,=0CD!^E$)&&06T$>!>&ZS:S]6K"U]D74,
MBF49"@8A\4!4X_/>E4,]D$M6&?#-,#WKQB8_55,IUO,_R]=7G68GU9?+N4%[
MM$P((@*U(&HDJ%-#K
378D5(#N!!G![(CNUI:/H@
MFFDY$VJA-[N#@&T
W[U='@2:"&B/*VGE42FN"O*OL/4QC
M@[8?.ONAL\^CLS77]8FS7'.%P:_&SV)/N+S.RDJK^E/T3]L7Q0_-G6INB@CI
M7?5AFANVW:SFOG20N@&L:Z;&*$Z0,D$JSS3 XVLTT@E?[C>7!J N@C$"NQB$
M/NH[ULC3&>-LEAK +M)(CYK!?JD@:A$S4<9@+F0)]CJGIEQCE9:#0Q[ B)D]
MEA<*F"XK@KP$Q+)]T_.PF!RPU_<2;S@Q\>SY.KZ^9F:*2?$=BS,#J]S#XM
^]P7>GIW9.>M_JPI7U[Z\3=P-6]+46E&Z_@"T=
M2*VWPG*PG/]2,T07$I$Z&!EB$)4=/6E:?'+P7<); 09ANI.=+,A7OZ#@U"\F
M8[PO8\(Z9V=A\ERF"<.#)PX!4L%[8+JPJ;(H#ZLJVU/#&K.S #7L:&Z0Z&3P
M[:7G3>SBO
?-$#B5/?JUE@-LG5C-8Q\Q_(!'$6
U$:7O\3.55>O"F>3*T,N]L,M.S,M
M:1M_PW7:JU7\[[E*,7/1J*;T:$?%3,M;Q>R7F[+:[+0,S_U^WBZ5JA>C=[ZS
M%['_4O![NY;]/5GZ#^:%?]T*FJ>L%GV;-'[D8.]?I__NAOKGC/1=,/6)V]O6
MGQ'Z, J]^G;--CN?F3D4%:SJJ&1@UWW\5K7[J<+=5QL[;%9[0
"@*G;PV09/H7A+G&%'E[Y IB R5O<81-I
M7V00YPZUNRB-A
ZETE]FF'%0RSW@Q/=*X:^6#U^?-8T%LG^YT'GH\8^Q1$.
M6^;BUB="$&OC'HRZ@(T1GKBA8<[)B53F[[O%$B%)V"=Z$/\ "+K[\RZ\WJJO
MBFQB EE?SHKD,/B4DZ 8X"+%(3 "+)R#&8SC0%[F1C\6Z^"2 0*=@+G(6/8A
MB9I'!L!$,=R/%@C9*@^[S@OH%7;HM)O8W/:+]73>JCI@W41SARWOHU+X=30$
M#H:#;>*#$^3NHYJI)M N*]XP;&7Q,"SV\BOI< ]1MIA&0QC9?/
SKV>/FGPTX8J5H6M#8U5';\/BIJ VKRLB(OX.V&G53+Q6D'O-@X
MK2H"F 9TI#K4YF]P*!T@ ZJ2< 5*"*-1[E3OH'@P?N(A'!0*V2G7O![)SI,]
MIF!^^C!:=$[!H@+RX8Z=&92.S^^ L3?+0*4!M51B[+.B*C6'!"@=[-T IP;N
M&PQ;(.4D:.^K.C%-@@:^J_H&Q"#:!,9MV?H$[>Z4+\H[>_NHYUB#*6OD@#6L
MI'9I#0G;ES6]F6!L0D F3AZ59<&",W(9@5Q?"<_[8:M!,!K@7X CCZQM8]&
M+(8-B>J&Q=TA!?$**[4*VY/B #WY0>!NT-GT_7!O&$BDG Z."D>634S!P HQ
M JAN2&0
E^,YL.+0^HU-"9K*30:;U1$5(@^[XVV>?2P8QM2$H,/R8N
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M,!%L#M^NHVK6F+'G/_=QK8R]D(.(HVY8
U@Y$0@42S!,S^:=_;GS+.UR+
M0=#L<
4U*Z-[@&?)1][DHX2V^AP&\RF;@58);SLI"VC1<71;6
MHF(0G?(E[%&X CXJ#QE1.P@5BT&HR+]@!8XIB[5*%EN."L$']!;%&G=Q(+H+
M$?=YA*G-1]F)J13AQU7[7D^7-ZPG'VJ_+7'AVQ%)24Q_B-DVB%F)N4"H@?L$
MU5A!@B79AH193HSX4=&[0761643,3D1AL2+Z<=P\#S<%;:K>M[UYDS4EF\<<
M1CU?T8C5'J(HG1-WKK"3XNC$/G276X@>8D!G( DLR7FX
TK^WI-G"%,+]*(>VWUX^U:B>7Q7:G^>*?
M97\C.:SXYX*# L2-3YTP\?>PG:;[O+HQX(6A_65;U#3?F" 5\R0^SR,'QY>Q
M+A6"7"!AD-UG12"%Z-CH!94/$FQN#AKL\XRR;\)+'![V/=UR8%#:RVQH_:-3
M:^*[RJW=#>R5,T^;'%KZX"T.['$!SPKQ#)84@EXQ#?R\(^\\4=A?NHRP]E.S
M3PL5UU+N:1KT,!BK1/7WOI+XBEQD^:E"4!M;^(#VVFCRX19I Y@?3PJ_A2)C
MUY/V%[#_^8T-)^DFT3DU-
U;:W/;QI+]*[-.W42J
M(BF2DFR)4ER7EN1<)Y:M2/(F7P? D)@(P" S "7FU]_3/0,")&5O;M:V*K6;
M*L<2,*_N/J=? Y_^5[]_4:2RB%4B_G5[^58D)JYS550BMDI6>'JOJU3
# 9
M'4T.#\7T4NQ\N#W;I=%IE6?XOY+)R]-<55+$J;1.5=\_^W#[NG_T[.5II:M,
MO3S=:_[V8R.3+%^>)GHA7+7,U/?/
S]2LFAP-CL;M(ZOGZ>J9<;K2D,6J3%9ZH6CM3^S
?X*_G;)Z]MT)CW;Z#X6%L*;?
M8Q($T_E<.!M__RR6I>V3
"W
8W&2
JL]^JA@\4[8YUNB@K,2P_;-]1K\(Z?F1(Y\!$CHV5MRF
M"K97=:5C)Z9%86JPVXF+ATH5#IH69B:NSC^\GHI;;*PJ,8W) .(
WLQ*R^F]&(F)";$>6<6*H^4%>-Q3["?FIDL,_=.N#K*M6M4162@B3(35ZET
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MM$K Q2J,=SU1F40NL9#G'BT@*Y[T87 S$*^-27B7
73GQ2I,62(*W
M&A0#D*=EF36 W &E=WEL2W-HL !H%PI0FLO 5:15\C2CZ_C5!6%$GGMXCJ3
M5B1+2&/*="EVSB_/88B9-3EA")ALV5:9;0H.GHH,4R=*:=F4I"M3S W! Q:-
M:_8$SN=!9 KRC]Y5,(+PY,
-%%G-4)9!X?]'/(E@I3*I!%1O# :N7-V0NQANGD
MI5Z8:MM5N:I.EMY7M>[,F@B**91S*P_6\V*2\_H=WK]JD4M26Q\+Z%?U ,BR
MG\.:!1[R,731N$#VG)]T@3,DFHYS18$I $&F\TC,0!AZW>-=H##8;"F@HA(&
MX56]1 .B/QWJVV_VCT^<...@P8!L@7ZQD%GM=Z-C7BOPT\:IV#E[=7&]"Y;$
MJJP"P5H[T!I>TIZ(==48V0%)>H;38TA=(&6%94F8#.*S9 )@7QV+&1QG$N"9
MZ;!%)Z[@I12Y_ U;M1M[Q],E_
TO@(EPX@HXD0':M6X$=]*)C-%T$
M5V>*)V,:Q8KQ\.07AEG1/? 2QB$#>V[UZ]*CVML;P%2B@(2IA)\V!8=PDBDW
M0&E@ WEP1! V"N$1Y03<: !S/@(SMANP8/U^&Q('9S4";QDD4AQ*6WT[3?C
M\>$)('F5#LX'('*JU0SYE(IKCAKO9X"%XK,W'!^((&?@'\&%Z;D!Z!Z"$6SH
MO3]G#:["3U B9(!3Z8(N4@7H1'[A<<(0?* D> >- .=!W6JWXSM6>
PI+@.Y,.AO<>'$(^=G/PRAQ9DAE ^.4KCT\",< E.
M&JA(%C@RF2#1LQGVX0H*I&BTSU%G77I222*!'Q)8.8H$%,21
7I'LUZLL+I$R?S":_0%-V=(H#V
MQ*]4WMR!9# YF!<3T(T%][CC!7#@1'\$;G?H0-DTR),HFA9J PDLQFU"
6PKO9VN(E#E@!R<2$<#XJ![ ^Q ZG<^SES0/B7$6.>7380\G'D0">H9:9
M:X++!T 6I[E!P M.S$='HI"GC1.166+U]] DYS,4+DE?H3)L
X>3I0I
MF7!&Q$HP^=* M*E/?OW &5A:DVGN4XUL4'M.TCP.+*0D6CE!?9=V\SJX)8PM
ML#+/9A_8%H%
/R FDBD0.4\J9V)=FH#VJ!0(F')B:?GSEN!G"-7IJRSE;@:7CBAW*MP_EE
MI)#GN-3<,]0I:6G2RC;6XA>JJB@ VSJ05GR]G#$)C<)[4%AUW>'*MV?Z0C<
MP5%]&K\BP6;(:DC]"(W7
MC#BER4&(NX)DY:8#-SY<0XY0?.0RIDV07'FFRHRJ+0B@+::4[+0,:
EDK[\(O73JSG*'/?P^#!AONNG[;5>_>_\0GG2O'S:O%TIHOQ]!
M+7=].8/Z)S*[ETL7.O!'X\'^X3].(@XMH<$^W+JP^/]KD/_3UR ;;M>KDWJ2
M/IIU",6_3V\OK[:(
"_FKYC1E85@"
M9H/C;)K^JP[?GVA;A\Z1;X=L!?VFK[Y62(9PKOY4'!^T6"'),M?5K>\6&;S'
M,@B1-Q4":97^BG+NX&A\TJA
9 (HI:NR.)"2A
M\!Y2>>>9[W)HM9^;3$$7:MV"%/JI10RK%7.?&:\L-VWQSI4XV34.K08&2S@$
M253X+B06;M375-.^-[ !"DH$
GD0B.Z7O*9\=[*U
M'%S55SG-:V1MD3%W_B1?9
P=.
M(9K-B>] _&O?MNR_A=WH=RYUR0,]=3QH#^)38>W8
3%@KZ?3L_"TJ0SVY2 WNNURP%'
M*25$34_7-VEP.*1(<*4FJJBST)T0
#O
MHIY):N;X3D?IE]=D$39,N/Q:[1":Q8VJVU!'I3+=$6IJ'W
]QOQ0L*N=3="CFX?]XT
M4$5--R,$L.;*,Y8N#0R@NW'>'IC!I%@Q0%: 1=U=!X.2FOTE^HF/N"T%6U#2
MONU #Y!WNJ1\^";5Q5+>U>+,(%M_6R4#7N;=#5WU(CSVQ)LB'G0A1Q9#$DZP
M"WTR*GYJ2JIH'Y3M4))LNE;-$2C=R_ ;-_MBI1)/C:8[W<$CQ7EE27.@;+
IYH%E7
MMIZ_'ICAA[D!5WK!%3#.#*/5^=LD7=7^>PEVVEEPVIW#D#U"ZR!<$32:12FS
MH.N#F];@;UL[7BO.T.A##8P?'1\?(G.B6YUV:284)4!$D
V@,?V]LXII+I7 _XE87G.$Y*V+S84Q
MU]N/5WS<>.'2QS;P6>OFTWN=95O/:'KSC)F$6$'Y>]N'
WPA0Y^\1"G7&3P=67X!*^@2WBH9/0B?#GD
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MP8OQB\'HQ>'A5[TY_=]>DRX,-/8_W)+N^7]7ML?_+.W?4$L! A0#% @
M+FL87>MCXI4# P :PH !$ ( ! &-A<'(M,C R-C X
M,C0N>'-D4$L! A0#% @ +FL871;R>9-H!0 GSL !4
M ( !,@, &-A<'(M,C R-C X,C1?;&%B+GAM;%!+ 0(4 Q0 ( "YK&%TM
M1[X.9 0 +,E 5 "
#DY
<9#$N:'1M4$L%!@ % 4 30$ *(S $!
end
XML
16
capr-20260824x8k_htm.xml
IDEA: XBRL DOCUMENT
0001133869
2026-08-24
2026-08-24
0001133869
false
8-K
2026-08-24
CAPRICOR THERAPEUTICS, INC.
DE
001-34058
88-0363465
10865 Road to the Cure, Suite 150
San Diego
CA
92121
858
727-1755
false
false
false
false
false
Common Stock, par value $0.001 per share
CAPR
NASDAQ